PT  - JOURNAL ARTICLE
AU  - Emanuele F. Osimo
AU  - Stefan P. Brugger
AU  - Antonio de Marvao
AU  - Toby Pillinger
AU  - Thomas Whitehurst
AU  - Ben Statton
AU  - Marina Quinlan
AU  - Alaine Berry
AU  - Stuart A. Cook
AU  - Declan P. O’Regan
AU  - Oliver D. Howes
TI  - Cardiac structure and function in schizophrenia: a cardiac MR imaging study
AID  - 10.1101/19008649
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19008649
4099  - http://medrxiv.org/content/early/2019/10/11/19008649.short
4100  - http://medrxiv.org/content/early/2019/10/11/19008649.full
AB  - Background Heart disease is the leading cause of death in schizophrenia.Aims We investigated cardiac structure and function in patients with schizophrenia using cardiac magnetic resonance imaging (CMR) after excluding medical and metabolic comorbidity.Methods 80 participants underwent CMR to determine biventricular volumes and function and measures of blood pressure, physical activity, and glycated haemoglobin levels. Patients and controls were matched for age, sex, ethnicity, and body surface area.Results Patients with schizophrenia had significantly smaller indexed left ventricular (LV) end-diastolic volume, end-systolic volume, stroke volume, right ventricular (RV) end-diastolic volume, end-systolic volume, and stroke volume but unaltered ejection fractions relative to controls. LV concentricity and septal thickness were significantly larger in schizophrenia. The findings were largely unchanged after adjusting for smoking or exercise levels and were independent of medication dose and duration.Conclusions Patients with schizophrenia show evidence of prognostically-adverse cardiac remodelling compared to matched controls, independent of conventional risk factors.Competing Interest StatementDr Osimo, Dr Brugger, Dr de Marvao, Dr Pillinger, Dr Whitehurst, Ms Berry, Ms Quinlan and Mr Statton report no conflicts of interest. Professor Cook is a co-founder and director of Enleofen Bio PTE LTD, a company that develops anti-IL-11 therapeutics. Enleofen Bio had no involvement in this study. Professor Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angelini, Autifony, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand, and Roche. Dr O’Regan has received grant funding from Bayer AG. None of these had any involvement in this study.Clinical TrialThis is a cross-sectional study but not a clinical trial.Funding StatementThis study was funded by grants MC-A656-5QD30 from the Medical Research Council-UK, and the NIHR Biomedical Research Centre South London and Maudsley Foundation NHS Trust to Professor Howes.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe dataset for this paper is available on Code Ocean together with the R analysis codes, which can be reproduced on the go (https://doi.org/10.24433/CO.9265392.v1). https://doi.org/10.24433/CO.9265392.v1